Home › Trial NCT06742138
To Evaluate the Efficacy and Safety of QL2109 and DARZALEX FASPRO® in Multiple Myeloma
- Trial IDNCT06742138
- StatusNot Yet Recruiting
- PhasePhase 3
- Study typeInterventional
- SponsorQilu Pharmaceutical Co., Ltd.
- Enrollment284
- Start date2025-01
- ConditionsMultiple Myeloma
Enriched analysis
Parsed endpoints, structured eligibility, drug class and a plain-English summary — shown to verified visitors to prevent automated scraping.
Trial data from ClinicalTrials.gov (U.S. public domain) and ISRCTN (CC BY 4.0), used with attribution. TrialLens is an independent index, not affiliated with or endorsed by ClinicalTrials.gov, the NIH, or any trial sponsor. For research only — not medical advice.